Innoviva Inc is primarily active in the healthcare and pharmaceutical industries.

The main competitors of Innoviva Inc in the market include pharmaceutical and biotechnology companies such as GlaxoSmithKline, Novartis, AstraZeneca, and Merck & Co.

Innoviva Inc, formerly known as Theravance Inc, is a biopharmaceutical company specializing in the development and commercialization of innovative therapies. Founded in 1996, Innoviva has a rich history of partnering with leading pharmaceutical companies to bring breakthrough treatments to market. With a focus on respiratory diseases, Innoviva is committed to improving the lives of patients suffering from conditions such as asthma and chronic obstructive pulmonary disease (COPD). The company has an impressive portfolio of products and continues to invest in research and development to address unmet medical needs. Innoviva's dedication to innovation and strategic collaborations has positioned it as a leader in the biopharmaceutical industry.

Innoviva Inc, a leading stock company, has achieved several significant milestones throughout its history. The company has successfully forged strategic partnerships with renowned pharmaceutical companies, facilitating the development and commercialization of innovative respiratory therapies. Innoviva Inc has also consistently delivered impressive financial results, showcasing its strong market position and value creation for shareholders. Furthermore, the company has been focused on enhancing its pipeline of respiratory products and expanding its global footprint. With its continued commitment to innovation and strategic growth, Innoviva Inc remains a prominent player in the stock market, presenting lucrative opportunities for investors.

Innoviva Inc is primarily present in the United States.

Innoviva Inc is committed to delivering value to its shareholders and stakeholders through innovation and collaboration. The company's corporate philosophy is focused on providing innovative solutions in the field of respiratory diseases. Innoviva Inc prides itself on fostering a culture of excellence, integrity, and patient-centricity. With a dedicated team and strategic partnerships, the company strives to enhance the quality of life for individuals suffering from respiratory conditions. Innoviva Inc's commitment to research, development, and commercialization of novel therapies underscores its mission to make a meaningful difference in the lives of patients worldwide.

Analysts currently set an average price target of 33.15 USD for the Innoviva stock (median: 33.66 USD), implying +57.0 % versus the latest price. The consensus is based on 10 analyst ratings.

Innoviva Analyst Price Targets 2026

10 analysts currently rate the Innoviva stock: 8 recommend buying, 1 holding and 1 selling. For 2026, analysts expect Innoviva to generate revenue of 440.56 M USD and earnings per share of 3.13 USD.

Innoviva Analyst Price Targets 2026

Converted at the current exchange rate, the Innoviva share trades at 17.89 EUR (20.63 USD).

The Innoviva share (INVA) is listed on 5 stock exchanges, including: NASDAQ (INVA), Frankfurt (HVE.F), München (HVE.MU), Düsseldorf (HVE.DU), SIX (Zürich) (HVE.SW).

Innoviva Inc. is a publicly traded company based in California, USA, that focuses on the development and marketing of medications in collaboration with its partners. The company has two main business areas: partnerships with the pharmaceutical industry and the sale of licenses. In the first area, Innoviva specializes in the development of medications for respiratory diseases and has partnerships with leading pharmaceutical companies such as GlaxoSmithKline and Theravance Biopharma. In the second area, Innoviva offers its extensive patent portfolio to partner companies for use and actively seeks potential partners who can benefit from certain patents. Overall, Innoviva has a strong position in the respiratory disease market and is known for its innovative and effective medications.

The expected revenue of Innoviva is 440.56 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Innoviva is 266.78 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Innoviva is currently 6.59. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Innoviva stock.

The price-to-sales ratio (P/S) of Innoviva is currently 3.99. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Innoviva stock.

The Eulerpool Quality Score for Innoviva is 5/10.

The ISIN of Innoviva is US45781M1018. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Innoviva is A2AC9U. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Innoviva is INVA. The ticker symbol is used to trade Innoviva shares on the stock exchange.

Over the past 12 months, Innoviva paid a dividend of 0.75 USD . This corresponds to a dividend yield of about 3.64 %. For the coming 12 months, Innoviva is expected to pay a dividend of 1.00 USD.

The current dividend yield of Innoviva is 3.64 %.

Innoviva pays a dividend, distributed in the months of , , , .

Innoviva paid dividends every year for the past 0 years.

For the upcoming 12 months, dividends amounting to 1.00 USD are expected. This corresponds to a dividend yield of 4.85 %.

Innoviva is assigned to the 'Health' sector.

To receive the latest dividend of Innoviva from amounting to 0.25 USD, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

The dividends of Innoviva are distributed in USD.